NLC Health Ventures introduces new venture transforming cardiovascular care

NLC Health Ventures launches Revadix, an innovative biotech venture focused on improving the lives of millions of patients with atrial fibrillation (AF). Unlike current treatments that mostly improve symptoms but are not curative, Revadix is developing a new therapy that targets specifically dysfunctional signalling, thus restoring normal sinus rhythm.

Atrial fibrillation is one of the most common heart rhythm disorders, affecting more than 33 million people worldwide. Patients often experience symptoms such as irregular heartbeats, fatigue, and an increased risk of stroke. 

Revadix is developing AM-001, a therapy that targets a specific protein called EPAC-1, which plays a key role in the genesis of the harmful processes that disrupt heart rhythm. This therapy has shown unparalleled efficacy in preclinical animal studies to prevent dangerous heart rhythm disturbances without interfering with the heart’s essential functions.

Revadix’s work builds on years of research by Dr. Frank Lezoualc’h at Inserm in Toulouse, France. “Working for more than a decade on exploring the therapeutic potential of EPAC-1 modulation, I believe that AM-001 drug compound can treat the cause and not only the consequence of the pathology” said Dr. Lezoualc’h. 

“This innovation has the potential to change the lives of millions. For patients, it means fewer side effects and a safer, more effective way to manage atrial fibrillation. Our ultimate goal is to give people their health and independence back,” said Dr. Hesham Hamed, CEO of Revadix. With the support of NLC Health Ventures, the company is advancing AM-001 through the next stages of development and is working towards clinical trials.

“Revadix addresses a real and urgent need in cardiovascular care. By focusing on the core problem in atrial fibrillation treatment, this venture has the opportunity to make a meaningful difference for patients and healthcare providers alike,” said Kathrin Ballesteros, Venture Partner at NLC Health Ventures. 

In addition to atrial fibrillation, the EPAC-1 pathway holds potential for addressing other cardiovascular conditions, offering hope for future advancements in heart health.

‍

About Revadix

Revadix is dedicated to improving the treatment of atrial fibrillation and other cardiovascular diseases. By developing AM-001, a therapy that specifically targets the EPAC-1 pathway, Revadix aims to deliver safer, more effective care to patients while reducing the burden on healthcare systems.

‍

About NLC Health Ventures

NLC Health Ventures, based in Amsterdam, is the most active health technology investor in Europe and the world’s largest healthtech venture builder. NLC finds, builds, and scales transformative health innovations with the goal of providing more patients with quality care. NLC is a so-called ‘BCorp,’ its funds comply with SFDR9 guidelines, and they contribute to ESG 3, 9, and 17. With more than 100 start-ups, 4 funds, and activity in 16 countries, they bring impactful innovations to patients on a large scale. The NLC Health Impact Fund is NLC’s newest and largest fund to date, investing in NLC’s start-ups. The fund deploys capital for ventures at various stages, providing both initial and follow-up funding.

‍

For more information:

Dr Hesham Hamed, CEO, Revadix

Email: info@revadix.com

Website: https://revadix.com/